Tiankang (301263.SZ) holding subsidiary CKBA Cream applied for children's vitiligo clinical trial and was accepted.

According to the Zhitong Finance APP, Tension (301263.SZ) announced that its controlling subsidiary, Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan"), recently received an acceptance notification from the National Medical Products Administration, agreeing to accept Bochuangyuan's submission of a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study application for the safety, tolerability, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrow-band ultraviolet B (NB-UVB) in children aged 2-12 (including 2-year-olds) with non-segmental vitiligo.